Zhitong Finance App News, ST Renfu (600079.SH) announced that the company's holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd. (“Yichang Renfu”, the company holds 80% of its shares), recently received the “Notice of Acceptance” of the drug registration and marketing license application for brixetam tablets approved and issued by the State Drug Administration. Buriracetam is an analogue of levetiracetam. It can selectively bind to synaptic vesicle protein 2A in the brain to exert an anti-seizure effect by affecting synaptic function. The indications for this application by Yichang Renfu are single drug treatment and additive treatment for partial seizures in patients with epilepsy aged 16 and above.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.